Primary hyperaldosteronism;
Conn’
s syndrome;
equilibrium angiotensin II;
renin;
aldosterone;
liquid chromatography-tandem mass spectrometry;
PRIMARY ALDOSTERONISM;
PREVALENCE;
D O I:
10.1177/00045632211008923
中图分类号:
R446 [实验室诊断];
R-33 [实验医学、医学实验];
学科分类号:
1001 ;
摘要:
Background The current first-line screening test for primary hyperaldosteronism is the plasma aldosterone:renin ratio; however, renin assays have several disadvantages and the ARR is affected by medications and physiological factors. Angiotensin II is a key biologically active hormone in the renin-angiotensin-aldosterone system. It has been suggested that measurement of equilibrium levels of this peptide, involving an in vitro incubation of serum prior to analysis, may provide a better marker of renin-angiotensin-aldosterone system activity than renin. Methods An eqAng II LC-MS/MS assay was developed, optimized and validated. Serum samples were incubated at 37 degrees C for 45 min prior to stabilization with cold EDTA solution, solid phase extraction and LC-MS/MS analysis. Stability in whole blood and the effect of cryoactivation were assessed. For comparison to the current screening test, 150 anonymized patients' samples were analysed for eqAng II, renin activity and aldosterone (all by LC-MS/MS). Results The assay had good precision, minimal bias and acceptable recovery. EqAng II did not change significantly when whole blood samples were stored for up to 72 h, and cryoactivation was only observed for pregnant patients. EqAng II was significantly correlated with renin, and the aldosterone:eqAng II ratio had a strong positive correlation with the aldosterone:renin ratio. Conclusions An LC-MS/MS assay for eqAng II has been developed which shows promise as an alternative screening test for primary hyperaldosteronism. Compared to renin assays, it is quicker, simpler and less likely to be affected by anti-hypertensive medications. Further clinical validation in hypertensive patients would be required prior to implementation.
机构:
Capital Med Univ, Beijing Shijingshan Hosp, Dept Pharm, Shijingshan Teaching Hosp, Beijing 100040, Peoples R ChinaCapital Med Univ, Beijing Shijingshan Hosp, Dept Pharm, Shijingshan Teaching Hosp, Beijing 100040, Peoples R China
Cui, Yanli
Wu, Feng
论文数: 0引用数: 0
h-index: 0
机构:
Capital Med Univ, Beijing Tongren Hosp, Natl Inst Drug Clin Trials, Beijing 100730, Peoples R ChinaCapital Med Univ, Beijing Shijingshan Hosp, Dept Pharm, Shijingshan Teaching Hosp, Beijing 100040, Peoples R China
机构:
Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USAUniv Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
Owusu, Benjamin Y.
Pflaum, Hannah
论文数: 0引用数: 0
h-index: 0
机构:
Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
Seattle Childrens Hosp, Seattle, WA 98105 USAUniv Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
Pflaum, Hannah
Garner, Russell
论文数: 0引用数: 0
h-index: 0
机构:
Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USAUniv Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
Garner, Russell
论文数: 引用数:
h-index:
机构:
Foulon, North
Laha, Thomas J.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USAUniv Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
Laha, Thomas J.
Hoofnagle, Andrew N.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
Univ Washington, Dept Med, Seattle, WA USAUniv Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA
Hoofnagle, Andrew N.
JOURNAL OF MASS SPECTROMETRY AND ADVANCES IN THE CLINICAL LAB,
2021,
19
: 1
-
6